ArticleExperimental and therapeutic medicine2020
Expression of microRNA-214 and galectin-3 in peripheral blood of patients with chronic heart failure and its clinical significance.
Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.
- Meta-analysis of a controlled study of levosimendan combined with Sacubitril/Valsartan for the treatment of heart failure with reduced ejection fraction in China.Frontiers in cardiovascular medicine · 2024Pooled it
- Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis.European journal of heart failure · 2022Pooled it
- The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- From Natriuretic Peptides to microRNAs: Multi-Analyte Liquid Biopsy Horizons in Heart Failure.Biomolecules · 2025Review
- Diagnostic value of echocardiography combined with serum C-reactive protein level in chronic heart failure.Journal of cardiothoracic surgery · 2023Article
- Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.Frontiers in network physiology · 2022Review
- The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.Biomolecules · 2021Review
- Cirrhotic Cardiomyopathy.Current gastroenterology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of microRNA (miR)-214 and galectin-3 (Gal-3) in peripheral blood of patients with chronic heart failure (CHF) and its clinical significance were investigated. A total of 50 cases of CHF patients, diagnosed and treated in Shanghai Xuhui Central Hospital from January 2017 to March 2018, were the study group and 30 healthy subjects who underwent physical examination during the same period were the control group. Concentration of serum Gal-3 was detected by ELISA and the expression of miR-214 in serum was detected by RT-qPCR. The expression of miR-214 and Gal-3 in the peripheral blood of CHF patients were analyzed. The diagnostic and predictive values of efficacy were analyzed by ROC curve analysis, and the correlation between miR-214 and Gal-3 was analyzed by Pearson's correlation analysis. The serum expression levels of miR-214 and Gal-3 in the observation group were significantly higher than those in the control group, with statistically significant difference (P<0.05). Pearson's correlation analysis revealed that the expression levels of miR-214 and Gal-3 were positively correlated in the peripheral blood of CHF patients (r=0.712, P<0.05). The area under curve (AUC) of miR-214 and Gal-3 for CHF diagnosis was 0.916 and 0.852, respectively (P<0.05). The AUC for predicting the efficacy of miR-214 and Gal-3 was 0.874 and 0.897, respectively (P<0.05). In conclusion, it is speculated that miR-214 and Gal-3 are involved in the occurrence and development of CHF, which is of guiding significance for the clinical diagnosis and monitoring of CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.